

New claims 15 and 19 are supported since it was known in the art as of the effective filing date of this application (June 10, 1993) that treatment of cervical dystonia with a botulinum toxin type A can result in alleviation of the pain which accompanies cervical dystonia. See e.g. Jankovic J., et al., *Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy*, Adv Neurol 50(2);583-91:1988, and Jankovic J., *Botulinum toxin injections in patients with cervical dystonia*, Neurology 39(3) supp 1;294:1989. The abstracts of both these articles are attached.

New claim 16 is supported by at least original claims 4 and 5.


Thus, no new matter is introduced by any of the claim amendments or by any of the new claims.

V. Conclusion

Examination and allowance of the pending claims 1, 4 and 11-19 is requested.

Respectfully Submitted,

Date: March 15, 2001


Stephen Donovan
Registration Number 33,433

Please direct all correspondence to:

Stephen Donovan
Legal Department
Allergan, Inc. T2 7H
2525 Dupont Drive
Irvine, California 92612
Telephone: 714 246 4026
Fax: 714 246 4249